Thallion Pharmaceuticals Inc.
TSX : TLN

Thallion Pharmaceuticals Inc.

October 04, 2007 13:15 ET

Thallion to Present ECO-4601 Human Pharmacokinetic Data at AACR-NCI-EORTC Conference

MONTREAL, QUEBEC--(Marketwire - Oct. 4, 2007) - Thallion Pharmaceuticals Inc. (TSX:TLN) announced today that it will be presenting a scientific poster and abstract at the AACR-NCI-EORTC 2007 International Conference on Molecular Targets and Cancer Therapeutics in San Francisco. The Company's poster will disclose the pharmacokinetic data from the Phase I/II clinical trial investigating ECO-4601 in advanced cancer patients. The poster session presentations will take place at the Moscone Convention Center West on Wednesday, October 24, from 12:30 pm to 2:30 pm and from 5:30 pm to 7:30 pm. Thallion's poster and abstract, number B-119, are titled: Phase I pharmacokinetic study of ECO-4601, a novel bifunctional targeting agent.

About ECO-4601

ECO-4601 is a novel small molecule derived from a nonpathogenic microorganism. It has demonstrated broad in vitro cytotoxic activity across a diverse panel of tumour cell lines and in vivo efficacy in a number of xenograft tumour models. Preclinical data suggest that ECO-4601 is a targeted anti-cancer agent with dual activity: selective binding to the peripheral benzodiazepine receptor (PBR) and inhibition of the Ras-MAPK pathway. Thallion has successfully completed the recruitment and administration of the extension phase of its ECO-4601 Phase I/II clinical trial. ECO-4601 was discovered using DECIPHER®, Thallion's proprietary genomics-based drug discovery platform.

About Thallion Pharmaceuticals Inc.

Thallion Pharmaceuticals Inc. (TSX:TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. Thallion has three active clinical programs at a Phase II, or later, stage of development which include: Shigamabs®, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections; ECO-4601, a novel anticancer therapy derived from a nonpathogenic microorganism; and CAP-232, a targeted therapy with potential efficacy in multiple oncology indications. Additional information about the Company can be obtained at www.thallion.com.

About the International Conference on Molecular Targets and Cancer Therapeutics

The International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications is organized through a partnership of the American Association of Cancer Research (AACR), the National Institute of Cancer (NCI) and the European Organization for Research and Treatment of Cancer (EORTC). It is a multidisciplinary conference attended by those who are leading the discovery and drug development effort against cancer worldwide. Overall, attendees at the Molecular Targets conference include senior level research scientists, heads of discovery and drug development from both industry and academia, as well as those in international and U.S. marketing of oncology products and those working on in-licensing and pipeline development. For more information about the actual conference, contact the Department of Communications and Public Relations at AACR 215-440-9300 or communications@aacr.org.

Forward-Looking Statements

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

Contact Information